FAGRON N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.52 EUR | +0.22% |
|
-1.91% | +11.50% |
| Apr. 11 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 | |
| Apr. 11 | Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 | CI |
| Sales 2024 * | 841M 910M | Sales 2025 * | 895M 968M | Capitalization | 1.35B 1.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 82M 88.66M | Net income 2025 * | 96M 104M | EV / Sales 2024 * | 1.88 x |
| Net Debt 2024 * | 228M 247M | Net Debt 2025 * | 177M 192M | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
14.1
x | Employees | 3,282 |
| Yield 2024 * |
1.58% | Yield 2025 * |
1.72% | Free-Float | 94.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fagron N.V.
More press releases
More news
| 1 day | +0.22% | ||
| 1 week | -1.91% | ||
| Current month | +1.54% | ||
| 1 month | +3.81% | ||
| 3 months | +3.00% | ||
| 6 months | +7.74% | ||
| Current year | +11.50% |
1 week
18.40
19.00
1 month
17.5419.06
Current year
16.5219.06
1 year
14.6419.06
3 years
10.8020.08
5 years
10.8023.26
10 years
3.7044.98
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 17-11-26 | |
Karin de Jong
DFI | Director of Finance/CFO | 45 | 08-04-30 |
Vera Bakker
COO | Chief Operating Officer | 52 | 22-05-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Koen Hoffman
CHM | Chairman | 56 | 16-07-31 |
| Director/Board Member | 64 | 18-12-31 | |
| Chief Executive Officer | 46 | 17-11-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.80% | 21 M€ | +2.66% | ||
| 0.01% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 18.52 | +0.22% | 31,468 |
| 24-05-22 | 18.48 | -1.49% | 21,698 |
| 24-05-21 | 18.76 | -0.64% | 77,786 |
| 24-05-20 | 18.88 | +0.53% | 33,666 |
| 24-05-17 | 18.78 | -0.53% | 39,754 |
Real-time Euronext Bruxelles, May 23, 2024 at 11:35 am EDT
More quotes
Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.52
EUR
Average target price
21.7
EUR
Spread / Average Target
+17.17%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.50% | 1.46B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- FAGR Stock
